Apexigen, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APGN research report →
Companywww.apexigen.com
Apexigen Inc. , a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells.
- CEO
- Xiaodong Yang
- IPO
- 2021
- Employees
- 11
- HQ
- San Carlos, CA, US
Price Chart
Valuation
- Market Cap
- $9.57M
- P/E
- -0.24
- P/S
- 0.00
- P/B
- 1.19
- EV/EBITDA
- 0.16
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 48.27%
- ROIC
- -493.64%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-31,452,000 · -8.92%
- EPS
- $-1.59 · -70.97%
- Op Income
- $-32,686,000
- FCF YoY
- -28.36%
Performance & Tape
- 52W High
- $8.28
- 52W Low
- $0.33
- 50D MA
- $0.43
- 200D MA
- $0.92
- Beta
- 3.62
- Avg Volume
- 262.33K
Get TickerSpark's AI analysis on APGN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 23, 23 | Zabrowksi Dan | sell | 100,000 |
| Aug 23, 23 | Wertheimer Samuel P | sell | 1,845 |
| Aug 23, 23 | Wertheimer Samuel P | sell | 146,383 |
| Aug 23, 23 | Wertheimer Samuel P | sell | 100,000 |
| Aug 23, 23 | Wertheimer Samuel P | sell | 12,383 |
| Aug 23, 23 | Smith Scott Andrew | sell | 34,084 |
| Aug 23, 23 | Smith Scott Andrew | sell | 100,000 |
| Aug 23, 23 | RINGOLD GORDON | sell | 5,000 |
| Aug 23, 23 | RINGOLD GORDON | sell | 100,000 |
| Aug 23, 23 | RINGOLD GORDON | sell | 10,000 |
Our APGN Coverage
We haven't published any research on APGN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate APGN Report →